Prevention of Cardiac Surgery–Associated Acute Kidney Injury by Implementing the KDIGO Guidelines in High-Risk Patients Identified by Biomarkers: The PrevAKI-Multicenter Randomized Controlled Trial
2021/03/08 by Alexander Zarbock, Mira Küllmar, Marlies Ostermann +33 · 31 citations
Medicine · #Acute Kidney Injury Research #Chronic Kidney Disease and Diabetes #Trauma, Hemostasis, Coagulopathy, Resuscitation
paper · doi:10.1213/ane.0000000000005458
Abstract
BACKGROUND: Prospective, single-center trials have shown that the implementation of the Kidney Disease: Improving Global Outcomes (KDIGO) recommendations in high-risk patients significantly reduced the development of acute kidney injury (AKI) after surgery. We sought to evaluate the feasibility of implementing a bundle of supportive measures based on the KDIGO guideline in high-risk patients undergoing cardiac surgery in a multicenter setting in preparation for a large definitive trial. METHODS: In this multicenter, multinational, randomized controlled trial, we examined the adherence to the KDIGO bundle consisting of optimization of volume status and hemodynamics, functional hemodynamic monitoring, avoidance of nephrotoxic drugs, and prevention of hyperglycemia in high-risk patients identified by the urinary biomarkers tissue inhibitor of metalloproteinases-2 [TIMP-2] and insulin growth factor-binding protein 7 [IGFBP7] after cardiac surgery. The primary end point was the adherence to the bundle protocol and was evaluated by the percentage of compliant patients with a 95% confidence interval (CI) according to Clopper-Pearson. Secondary end points included the development and severity of AKI. RESULTS: In total, 278 patients were included in the final analysis. In the intervention group, 65.4% of patients received the complete bundle as compared to 4.2% in the control group (absolute risk reduction [ARR] 61.2 [95% CI, 52.6-69.9]; P < .001). AKI rates were statistically not different in both groups (46.3% intervention versus 41.5% control group; ARR -4.8% [95% CI, -16.4 to 6.9]; P = .423). However, the occurrence of moderate and severe AKI was significantly lower in the intervention group as compared to the control group (14.0% vs 23.9%; ARR 10.0% [95% CI, 0.9-19.1]; P = .034). There were no significant effects on other specified secondary outcomes. CONCLUSIONS: Implementation of a KDIGO-derived treatment bundle is feasible in a multinational setting. Furthermore, moderate to severe AKI was significantly reduced in the intervention group.
Cited by
- The Path to Precision in Acute Kidney Injury
- Sepsis-associated acute kidney injury—treatment standard
- Inferior vena cava ultrasound and other techniques for assessment of intravascular and extravascular volume: an update
- Prediction of Acute Kidney Injury After Cardiac Surgery With Combined Arterial and Venous Intrarenal Doppler
- Ten tips on how to reduce iatrogenic acute kidney injury
- Impact of Using Biomarkers in Eligibility Criteria in Acute Kidney Injury Randomized Controlled Trials: A Systematic Review and Methodological Meta-Analysis
- Biomarkers in Cardiorenal Syndrome. [europepmc]
- Diagnosis of Cardiac Surgery-Associated Acute Kidney Injury. [europepmc]
- Cardiac Surgery Associated AKI Prevention Strategies and Medical Treatment for CSA-AKI. [europepmc]
- The AKI care bundle: all bundle components are created equal-are they? [europepmc]
- CSA-AKI: Incidence, Epidemiology, Clinical Outcomes, and Economic Impact. [europepmc]
- Overcoming barriers in the design and implementation of clinical trials for acute kidney injury: a report from the 2020 Kidney Disease Clinical Trialists meeting. [europepmc]
- Predictive Accuracy of a Perioperative Laboratory Test-Based Prediction Model for Moderate to Severe Acute Kidney Injury After Cardiac Surgery. [europepmc]
- Overview of Diagnostic Criteria and Epidemiology of Acute Kidney Injury and Acute Kidney Disease in the Critically Ill Patient. [europepmc]
- The Intensivist's Perspective of Shock, Volume Management, and Hemodynamic Monitoring. [europepmc]
- Performance of a Standardized Clinical Assay for Urinary C-C Motif Chemokine Ligand 14 (CCL14) for Persistent Severe Acute Kidney Injury. [europepmc]
- Heart Failure and Cardiorenal Syndrome: A Narrative Review on Pathophysiology, Diagnostic and Therapeutic Regimens-From a Cardiologist's View. [europepmc]
- Diagnosis, pathophysiology and preventive strategies for cardiac surgery-associated acute kidney injury: a narrative review. [europepmc]
- Adverse renal effects associated with cardiopulmonary bypass. [europepmc]
- Analysis of urinary C-C motif chemokine ligand 14 (CCL14) and first-generation urinary biomarkers for predicting renal recovery from acute kidney injury: a prospective exploratory study. [europepmc]
- Biomarker-guided intervention to prevent acute kidney injury after major surgery (BigpAK-2 trial): study protocol for an international, prospective, randomised controlled multicentre trial. [europepmc]
- Performance of urinary C-C motif chemokine ligand 14 for the prediction of persistent acute kidney injury: a systematic review and meta-analysis. [europepmc]
- Acute Kidney Injury after Cardiac Surgery: Prediction, Prevention, and Management. [europepmc]
- Improvement of composite kidney outcomes by AKI care bundles: a systematic review and meta-analysis. [europepmc]
- Inferior vena cava ultrasound and other techniques for assessment of intravascular and extravascular volume: an update. [europepmc]
- Proenkephalin as a biomarker correlates with acute kidney injury: a systematic review with meta-analysis and trial sequential analysis. [europepmc]
- Cardiac Surgery-Associated Acute Kidney Injury. [europepmc]
- The Road to Precision Medicine for Acute Kidney Injury. [europepmc]
- Enhancing sepsis biomarker development: key considerations from public and private perspectives. [europepmc]
- Biomarkers in acute kidney injury. [europepmc]
- Development and validation of a real-time prediction model for acute kidney injury in hospitalized patients. [europepmc]
Related